Solriamfetol: Difference between revisions
| [unchecked revision] | [unchecked revision] |
MDElliottMD (talk | contribs) Recategorize: Stimulants -> Psychostimulants |
MDElliottMD (talk | contribs) Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved. |
||
| Line 2: | Line 2: | ||
| brand = Sunosi | | brand = Sunosi | ||
| classes = Norepinephrine-dopamine reuptake inhibitor (NDRI), wake-promoting agent | | classes = Norepinephrine-dopamine reuptake inhibitor (NDRI), wake-promoting agent | ||
| mechanism = Selective dopamine and norepinephrine reuptake inhibitor (DAT and NET inhibition). Unlike amphetamine, does not significantly release monoamines | | mechanism = Selective dopamine and norepinephrine reuptake inhibitor (DAT and NET inhibition). Unlike amphetamine, does not significantly release monoamines, pure reuptake inhibition. | ||
| uses = Excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea (OSA) | | uses = Excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea (OSA) | ||
| starting_dose = Narcolepsy: 75 mg PO once daily upon awakening, titrate every 3 days. OSA: 37.5 mg PO once daily, titrate. | | starting_dose = Narcolepsy: 75 mg PO once daily upon awakening, titrate every 3 days. OSA: 37.5 mg PO once daily, titrate. | ||
| Line 14: | Line 14: | ||
| pregnancy = Limited data; pregnancy exposure registry available | | pregnancy = Limited data; pregnancy exposure registry available | ||
| legal = Rx, Schedule IV (US) | | legal = Rx, Schedule IV (US) | ||
| intro = '''Solriamfetol''' (brand name Sunosi) is a selective dopamine and norepinephrine reuptake inhibitor (NDRI) approved by the FDA in March 2019 for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea. Unlike traditional stimulants (amphetamine, methylphenidate), solriamfetol does not significantly release monoamines from vesicles | | intro = '''Solriamfetol''' (brand name Sunosi) is a selective dopamine and norepinephrine reuptake inhibitor (NDRI) approved by the FDA in March 2019 for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea. Unlike traditional stimulants (amphetamine, methylphenidate), solriamfetol does not significantly release monoamines from vesicles, it is purely a reuptake inhibitor, which may produce a smoother subjective effect with lower abuse potential. Lower scheduled (CIV) than the traditional stimulants (CII). Not indicated to treat underlying OSA (use with primary OSA therapy such as CPAP). | ||
| pharmacodynamics= Selective inhibitor of DAT and NET. Modest serotonin reuptake inhibition. Does not bind VMAT2 or cause significant monoamine release (contrast with amphetamine). | | pharmacodynamics= Selective inhibitor of DAT and NET. Modest serotonin reuptake inhibition. Does not bind VMAT2 or cause significant monoamine release (contrast with amphetamine). | ||
| effects = Headache, nausea, decreased appetite, anxiety, insomnia, palpitations, blood pressure / heart rate elevation. Avoid in patients with significant cardiovascular disease. | | effects = Headache, nausea, decreased appetite, anxiety, insomnia, palpitations, blood pressure / heart rate elevation. Avoid in patients with significant cardiovascular disease. | ||
Revision as of 03:16, 19 May 2026
Norepinephrine-dopamine reuptake inhibitor (NDRI), wake-promoting agent
Solriamfetol
Sunosi
Solriamfetol (brand name Sunosi) is a selective dopamine and norepinephrine reuptake inhibitor (NDRI) approved by the FDA in March 2019 for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea. Unlike traditional stimulants (amphetamine, methylphenidate), solriamfetol does not significantly release monoamines from vesicles, it is purely a reuptake inhibitor, which may produce a smoother subjective effect with lower abuse potential. Lower scheduled (CIV) than the traditional stimulants (CII). Not indicated to treat underlying OSA (use with primary OSA therapy such as CPAP).
Selective inhibitor of DAT and NET. Modest serotonin reuptake inhibition. Does not bind VMAT2 or cause significant monoamine release (contrast with amphetamine).
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
Headache, nausea, decreased appetite, anxiety, insomnia, palpitations, blood pressure / heart rate elevation. Avoid in patients with significant cardiovascular disease.
Pharmacodynamics
Interactions
No interactions reported yet.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Classes
Norepinephrine-dopamine reuptake inhibitor (NDRI), wake-promoting agent
Common uses
Excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea (OSA)
Pharmacy
Starting dose
Narcolepsy: 75 mg PO once daily upon awakening, titrate every 3 days. OSA: 37.5 mg PO once daily, titrate.
Preparations
75 mg, 150 mg tablets
US FDA Max
150 mg/d
Pharmacology
Routes
Oral
Onset
~30-60 min
Duration
~9 hours
Half-life
~7.1 hours
Bioavailability
~95%
Pregnancy
Limited data; pregnancy exposure registry available
Legal status
Rx, Schedule IV (US)
Purported mechanism
Selective dopamine and norepinephrine reuptake inhibitor (DAT and NET inhibition). Unlike amphetamine, does not significantly release monoamines, pure reuptake inhibition.